Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025
Translational and Clinical Pharmacology · 2026 · 34 (1) · 69
DOI: 10.12793/tcp.2026.34.e3 ↗Kurz gefasst
Korrektur in der Zeitschrift Translational and Clinical Pharmacology, 2026. Verfasst von Seoyoung Koo und 6 weiteren Autor:innen. Beteiligte Einrichtung: MediRama, Inc., Seoul 06927, Korea. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- MediRama, Inc., Seoul 06927, Korea.
- Department of Medicine, Chosun University College of Medicine, Gwangju 61452, Korea.
- College of Pharmacy, Chungnam National University, Daejeon 34134, Korea.
ORCID-Profile: Seoyoung Koo, Hanlim Moon
Zitieren
APA
Koo, S., Kim, C. Y., Lim, J. H., Lee, E., Kim, I. Y., Shin, Y. G., & Moon, H. (2026). Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025. Translational and Clinical Pharmacology, 34(1), 69. https://doi.org/10.12793/tcp.2026.34.e3
Vancouver
Koo S, Kim CY, Lim JH, Lee E, Kim IY, Shin YG, et al. Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025. Translational and Clinical Pharmacology. 2026;34(1):69. doi:10.12793/tcp.2026.34.e3
BibTeX
@article{Koo2026,
author = {Koo, Seoyoung and Kim, Chae Yeon and Lim, Jeong Hyeon and Lee, Eunyoung and Kim, In Young and Shin, Young G and Moon, Hanlim},
title = {Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025},
journal = {Translational and Clinical Pharmacology},
year = {2026},
volume = {34},
number = {1},
pages = {69},
doi = {10.12793/tcp.2026.34.e3}
}
EUVIMED